Grufity logoGrufity logo

Sarepta Therapeutics Inc Stock Research

SRPT

149.67USD+4.20(+2.89%)Market Closed

Market Summary

USD149.67+4.20
Market Closed
2.89%

SRPT Alerts

SRPT Stock Price

SRPT RSI Chart

SRPT Valuation

Market Cap

13.2B

Price/Earnings (Trailing)

-18.71

Price/Sales (Trailing)

14.11

EV/EBITDA

-20.2

Price/Free Cashflow

-36.96

SRPT Price/Sales (Trailing)

SRPT Profitability

EBT Margin

-73.95%

Return on Equity

-182.75%

Return on Assets

-22.49%

Free Cashflow Yield

-2.71%

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

933.0M

Revenue Y/Y

28.28%

Revenue Q/Q

12.23%

SRPT Earnings

Earnings (TTM)

-703.5M

Earnings Y/Y

10.44%

Earnings Q/Q

57.61%

Price Action

52 Week Range

61.28159.84
(Low)(High)

Last 7 days

-4.9%

Last 30 days

21.0%

Last 90 days

16.7%

Trailing 12 Months

91.0%

SRPT Financial Health

Current Ratio

4.13

SRPT Investor Care

Shares Dilution (1Y)

0.94%

Diluted EPS (TTM)

-8.03

Peers (Alternatives to Sarepta Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
304.8B
1.4B
-3.73% 61.04%
-152.12
215.28
20.37% -37.45%
275.0B
58.1B
0.21% 1.63%
23.24
4.74
3.30% 2.55%
80.1B
12.2B
-0.48% 14.17%
18.47
6.58
-24.26% -46.28%
77.3B
8.9B
-1.64% 19.14%
23.26
8.65
17.91% 41.84%
23.5B
1.0B
-16.46% 21.47%
-20.78
22.66
22.88% -32.64%
13.2B
933.0M
21.02% 90.98%
-18.71
14.11
32.93% -67.99%
10.1B
1.9B
-15.04% 21.63%
13.93
5.23
14.88% 52.86%
MID-CAP
4.5B
504.0K
-6.48% 165.34%
-15.07
2.5K
-66.53% -22.12%
2.8B
363.3M
-7.03% -36.05%
-3.99
7.77
3.39% -55.81%
2.7B
204.0M
2.71% -22.88%
-4.84
13.22
13.30% 13.44%
2.5B
12.4M
-10.70% -44.17%
-3.35
199.44
- -27.34%
SMALL-CAP
1.6B
191.8M
-7.72% 90.19%
24.49
8.55
43.59% 60.82%
429.6M
93.0M
-0.16% -22.78%
-2.25
4.62
-19.83% -30.37%
24.0M
-
-31.83% 665.59%
-0.57
19.11
-77.61% 7.22%
3.5M
94.6M
-15.04% 9.81%
-0.01
0.04
34.30% -80.65%

Financials for Sarepta Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue6.5%933,013,000876,047,000835,184,000765,786,000701,887,000
  S&GA Expenses10.4%451,421,000408,998,000365,338,000283,369,000282,660,000
Costs and Expenses4.1%1,469,214,0001,411,228,0001,273,468,0001,160,512,0001,161,597,000
EBITDA1.3%-603,681,000-611,595,000-404,838,000-252,225,000-
EBITDA Margin7.3%-0.65-0.70-0.48-0.33-
Earnings Before Taxes2.9%-689,963,000-710,546,000-502,035,000-355,701,000-418,948,000
EBT Margin8.8%-0.74-0.81-0.60-0.46-
Interest Expenses-22.7%44,418,00057,495,00055,949,00055,949,00055,949,000
Net Income1.8%-703,488,000-716,225,000-506,631,000-356,555,000-418,780,000
Net Income Margin7.8%-0.75-0.82-0.61-0.47-
Free Cahsflow-24.0%-356,170,000-287,346,000-347,721,000-386,868,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-0.9%3,1283,1562,9973,0563,148
  Current Assets-2.6%2,5582,6262,4692,5312,604
    Cash Equivalents-6.9%9671,0398691,2342,116
  Inventory-7.8%204221208199186
  Net PPE-0.5%180181183187191
Liabilities0.7%2,7432,7252,2702,1992,220
  Current Liabilities2.8%620603546455453
Shareholder's Equity-10.7%385431726857928
  Retained Earnings-2.9%-3,910-3,800-3,543-3,311-3,206
  Additional Paid-In Capital1.5%4,2974,2354,2724,1694,135
Shares Outstanding0.2%88.0088.0088.0087.0087.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-24.0%-325-262-321-363-443
  Share Based Compensation9.8%233212189115114
Cashflow From Investing1.2%-1,046-1,059-1,058-447495
Cashflow From Financing-69.8%233771560564562

Risks for SRPT

What is the probability of a big loss on SRPT?

89.2%


Probability that Sarepta Therapeutics stock will be more than 20% underwater in next one year

81.2%


Probability that Sarepta Therapeutics stock will be more than 30% underwater in next one year.

39.2%


Probability that Sarepta Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SRPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Sarepta Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for SRPT

Cumulative Returns on SRPT

16.3%


10-Year Cumulative Returns

39.0%


7-Year Cumulative Returns

12.5%


5-Year Cumulative Returns

13.4%


3-Year Cumulative Returns

What are the long-term rolling returns for SRPT?

FIve years rolling returns for Sarepta Therapeutics.

Annualized Returns

Which funds bought or sold SRPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-70.84
-14,294,000
7,421,950
0.01%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
3,786
25,786
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-73.49
-575,000
259,000
-%
2023-03-06
Rockefeller Capital Management L.P.
new
-
1,000
1,000
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
unchanged
-
1,662
11,662
0.01%
2023-02-28
Voya Investment Management LLC
added
24.24
2,403,420
7,668,420
0.01%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
-56.00
1,944
-%
2023-02-24
NATIXIS
reduced
-21.99
-1,301,070
13,903,900
0.08%
2023-02-21
Empowered Funds, LLC
new
-
3,010,790
3,010,790
0.20%
2023-02-21
MACQUARIE GROUP LTD
reduced
-21.2
-379,000
3,318,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying SRPT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SRPT
No. of Funds

Sarepta Therapeutics News

PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ....

PR Newswire,
4 hours ago

Investor's Business Daily

Schedule 13G FIlings of Sarepta Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
sands capital management, llc
2.5%
2,151,378
SC 13G/A
Feb 10, 2023
janus henderson group plc
6.9%
6,028,016
SC 13G/A
Feb 09, 2023
vanguard group inc
9.15%
8,033,264
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
5,557,234
SC 13G/A
Feb 14, 2022
sands capital management, llc
6.16%
5,364,627
SC 13G
Feb 11, 2022
janus henderson group plc
8.3%
7,245,862
SC 13G
Feb 10, 2022
vanguard group inc
9.54%
8,311,108
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
6.1%
5,285,234
SC 13G/A
Aug 10, 2021
capital research global investors
4.8%
3,842,491
SC 13G/A

SRPT Fair Value

Sarepta Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Sarepta Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.77

-98.82%

3.92

-97.38%

10.58

-92.93%

23.14

-84.54%

48.53

-67.58%
Current Inflation

1.61

-98.92%

3.53

-97.64%

9.30

-93.79%

20.03

-86.62%

41.62

-72.19%
Very High Inflation

1.42

-99.05%

3.04

-97.97%

7.78

-94.80%

16.42

-89.03%

33.66

-77.51%

Historical Sarepta Therapeutics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Sarepta Therapeutics

View All Filings
Date Filed Form Type Document
Mar 10, 2023
4
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading

Latest Insider Trading transactions for SRPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-08
Estepan Ian Michael
sold (taxes)
-113,973
153
-744
chief financial officer
2023-03-08
Brown Ryan Edward
sold (taxes)
-97,275
153
-635
svp, general counsel
2023-03-08
Arif Bilal
sold (taxes)
-48,101
153
-314
chief tech ops officer
2023-03-08
Rodino-Klapac Louise
sold (taxes)
-139,709
153
-912
head of r&d, cso
2023-03-06
Mayo Stephen
acquired
-
-
1,523
-
2023-03-06
Nicaise Claude
acquired
-
-
1,523
-
2023-03-06
Rodino-Klapac Louise
acquired
-
-
4,500
head of r&d, cso
2023-03-06
Wigzell Hans Lennart Rudolf
acquired
-
-
1,523
-
2023-03-06
Arif Bilal
acquired
-
-
4,500
chief tech ops officer
2023-03-06
Estepan Ian Michael
sold (taxes)
-215,378
157
-1,370
chief financial officer

1–10 of 50

Douglas S. Ingram
840
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Products, net$ 843,769$ 612,401$ 455,865
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Collaboration and other$ 89,244$ 89,486$ 84,234
Total revenues933,013701,887540,099
Cost and expenses:   
Cost of sales (excluding amortization of in-licensed rights)139,98997,04963,382
Research and development877,090771,182722,343
Selling, general and administrative451,421282,660317,875
Settlement and license charges010,0000
Amortization of in-licensed rights714706662
Total cost and expenses1,469,2141,161,5971,104,262
Operating loss(536,201)(459,710)(564,163)
Other (loss) income, net:   
Loss on debt extinguishment(125,441)00
Gain (loss) on contingent consideration, net*[1]6,7007,200(45,000)
Gain from sale of Priority Review Voucher0102,000108,069
Other expense, net(35,021)(68,438)(51,971)
Total other (loss) income, net(153,762)40,76211,098
Loss before income tax (benefit) expense(689,963)(418,948)(553,065)
Income tax expense (benefit)13,525(168)1,063
Net loss(703,488)(418,780)(554,128)
Other comprehensive loss:   
Unrealized losses on investments, net of tax(1,644)(23)(47)
Total other comprehensive loss(1,644)(23)(47)
Comprehensive loss$ (705,132)$ (418,803)$ (554,175)
Net loss per share - basic and diluted$ (8.03)$ (5.15)$ (7.11)
Net loss per share - basic and diluted$ (8.03)$ (5.15)$ (7.11)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share87,559,00081,262,00077,956,000
Weighted average number of shares of common stock used in computing basic and diluted net loss per share87,559,00081,262,00077,956,000
[1]

* The gain (loss) on contingent consideration, net is related to the fair value adjustment of the regulatory-related contingent payments that are accounted for as derivatives. Please see Note 5. Fair Value Measurements for further details.

SRPT Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 966,777$ 2,115,869
Short-term investments1,022,5970
Accounts receivable214,628152,990
Inventory203,968186,212
Other current assets149,891149,028
Total current assets2,557,8612,604,099
Property and equipment, net180,037191,156
Intangible assets, net7,57814,239
Right of use assets64,95445,531
Other non-current assets317,936292,949
Total assets3,128,3663,147,974
Current liabilities:  
Accounts payable95,87576,741
Accrued expenses418,996271,697
Deferred revenue, current portion89,24489,244
Other current liabilities15,48915,051
Total current liabilities619,604452,733
Long-term debt1,544,2921,096,876
Lease liabilities, net of current portion57,57841,512
Deferred revenue, net of current portion485,000574,244
Contingent consideration36,90043,600
Other non-current liabilities4211,000
Total liabilities2,743,4162,219,965
Commitments and contingencies (Note 21)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding00
Common stock, $0.0001 par value, 198,000,000 shares authorized; 87,950,117 and 87,126,974 issued and outstanding at December 31, 2022 and 2021, respectively99
Additional paid-in capital4,296,8414,134,768
Accumulated other comprehensive loss, net of tax(1,664)(20)
Accumulated deficit(3,910,236)(3,206,748)
Total stockholders’ equity384,950928,009
Total liabilities and stockholders’ equity$ 3,128,366$ 3,147,974